Binder-drug conjugates (ADCs) and use thereof

US8992932B2 · kind B2 · utility

Assignee

• SEATTLE GENETICS, INC. · US

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Lars Linden · Mülheim an der Ruhr, DE
• Sherif El Sheikh · Essen, DE
• Jörg Willuda · Berlin, DE
• Charlotte Christine Kopitz · Berlin, DE
• Joachim Schuhmacher · Wuppertal, DE
• Simone Greven · Dormagen, DE
• Christoph MAHLERT · Wuppertal, DE
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Sven Golfier · Berlin, DE
• Rudolf BEIER · Berlin, DE
• Iring Heisler · Wuppertal, DE
• Axel Harrenga · Wuppertal, DE
• Karl-Heinz Thierauch · Berlin, DE
• Sandra Bruder · Leverkusen, DE
• Heike PETRUL · Berlin, DE
• Hannah Jörißen · Heiligenhaus, DE
• Sandra Borkowski · Hohen Neuendorf, DE

Key dates

• Filing date: Oct 20, 2012
• Grant date: Mar 31, 2015
• Expiry date: Oct 20, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.